

## References

### I-193

1. Vyxeos (daunorubicin and cytarabine) liposome, for injection, for intravenous use [prescribing information] Jazz Pharmaceuticals, Inc., Palo Alto, CA. 07/2019.
2. National Comprehensive Cancer Network (NCCN). Daunorubicin and Cytarabine Liposome NCCN Drugs & Biologics Compendium.
3. Clinical Pharmacology Compendia. 2020 Tampa FL: Gold Standard, Inc. Daunorubicin and cytarabine liposome.
4. Stein E & Tallman M. Emerging Therapeutic Drugs for AML. *Blood*. 2016;157:71-78.
5. Chen E, Fathi A & Brunner A. Reformulating Acute Myeloid Leukemia: Liposomal Cytarabine and Daunorubicin (CPX-351) as an Emerging Therapy for Secondary AML. *Onco Targets and Therapy*. 2018;11:3425-3434.
6. Micromedex DrugDex Compendium®. 2020. Daunorubicin and cytarabine liposome.
7. Blair, H. A.. Daunorubicin/Cytarabine Liposome: A review in acute myeloid leukemia. *Drugs*, 2018. 78(18): 1903-1910.
8. Krauss AC, Gao X., Li L, et. al. FDA approval summary:(daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia. *Clinical Cancer Research*. 2019. 25(9):2685-2690.